Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients with Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)
Jason R. Westin(The University of Texas MD Anderson Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Matthew L. Ulrickson, Christina To(Aadi (United States)), Marie José Kersten(Hovon), Simone Filosto(Kite (United States)), Caron A. Jacobson(Dana-Farber Cancer Institute), Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Justin A. Budka(Gilead Sciences (United Kingdom)), Saran Vardhanabhuti, Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Peter Vandenberghe(KU Leuven), Aaron P. Rapoport(University of Maryland, Baltimore), David B. Miklos(Stanford University), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Armin Ghobadi(Washington University in St. Louis), Umar Farooq(Wake Forest University), Yin Yang(Trinity College Dublin), Michael Dickinson(The University of Melbourne), Mahmoud Elsawy(Dalhousie University), Sridhar Chaganti(Cutaneous Lymphoma Foundation), Lori A. Leslie(Hackensack University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k